On June 13, 2014 Vialogy plc announced that a circular, comprising an admission document ("Admission Document") and a notice of general meeting, has been posted to shareholders.


The Company is pleased to announce that it has conditionally acquired the entire issued share capital of Premaitha, which is a molecular diagnostic company. The consideration of ₤10.5 million is to be satisfied by the issue of 95,454,545 New Ordinary Shares at a price of 11 pence per share. The Company has raised ₤6.5 million (before expenses) by means of the Placing and intends to raise up to a further ₤0.7 million by means of the Open Offer. The net proceeds of the Placing and the Open Offer will be used to develop and commercialise the IONA® Test, a non-invasive pre-natal screening test for Down's syndrome developed by Premaitha, and for general working capital purposes.

The Acquisition, if completed, is of sufficient size to constitute a reverse takeover under the AIM Rules and therefore is subject to the approval of shareholders at a General Meeting to be held at 11.00 a.m. on 3 July 2014 at the offices of Panmure Gordon (UK) Limited, One New Change, London EC4M 9AF.

A copy of the circular may be downloaded below

Admission document
Proxy form for general meeting on 3 July 2014

Following publication of the Admission Document, the temporary suspension to trading in the Company's shares will be lifted with effect from 7:30 a.m. on June 13 2014 and trading in the Company's shares will resume at 8:00 a.m.